Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2835219 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy sterile males or surgically sterile or postmenopausal females~* Have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m\^2), inclusive, at screening~* Are able to eat a high-fat, high-calorie meal~Exclusion Criteria:~* Participated in a clinical trial involving investigational product within 30 days~* Abnormal blood pressure~* Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study~* Have donated blood of more than 500 milliliter (mL) within the last month~* Show evidence of human immunodeficiency virus, hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY2835219 Standard (Type: EXPERIMENTAL): Single oral dose of LY2835219 given with a standard meal in one of three study periods.
- LY2835219 Fasted (Type: EXPERIMENTAL): Single oral dose of LY2835219 given with no food in one of three periods.
- LY2835219 High-Fat (Type: EXPERIMENTAL): Single oral dose of LY2835219 given with a high fat meal in one of three periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).